The EWS/TEC gene fusion generated by the t(9;22) chromosomal translocation found in extraskeletal myxoid chondrosarcomas encodes a fusion protein containing the amino-terminal domain of the EWS protein fused to the whole coding sequence of the orphan nuclear receptor TEC. We have compared the DNA-binding and transcriptional activation properties of various TEC isoforms and the corresponding EWS/TEC fusion proteins. Band-shift experiments show that the fulllength TEC receptor can eciently bind the NGFI-B Response Element (NBRE), whereas an isoform lacking the entire carboxyl-terminal domain of the receptor binds much less eciently the NBRE. Addition of the aminoterminal domain of EWS to either isoforms does not alter signi®cantly their DNA-binding properties to the NBRE. Co-transfection experiments of COS cells and human chondrocytes indicate that whereas TEC moderately activates transcription from a NBRE-containing promoter, the corresponding EWS/TEC fusion protein is a highly potent transcriptional activator of the same promoter, being approximately 270-fold more active than the native receptor. EWS/TEC may thus exert its oncogenic potential in chrondrosarcomas by activating the transcription of target genes involved in cell proliferation.
Introduction
The EWS gene is involved in various human malignancies by way of chromosomal translocation. It was originally discovered as being fused to the transcription factor FLI-1 by the t(11;22) chromosomal translocation found in the Ewing's sarcoma family of tumors (Delattre et al., 1992) . Subsequently EWS was found to be fused to various other transcription factors in Ewing's sarcoma, such as ERG, ETV1, E1AF and FEV (Zucman et al., 1993a; Sorensen et al., 1994; Jeon et al., 1995; Kaneko et al., 1996; Uranol et al., 1996; Peter et al., 1997) . In other tumor types, it was found that EWS could be fused to ATF-1 in malignant melanoma of the soft parts, to WT1 in desmoplastic small round cell tumors and to CHOP in myxoid liposarcoma (Zucman et al., 1993b; Ladanyi and Gerald, 1994; Panagopoulos et al., 1996) . The function of the EWS protein is not known, however it possesses an RNA-binding domain (Ohno et al., 1994) , suggesting that it may be involved in RNA metabolism. Supporting this possibility, a protein highly similar to EWS, called TLS/FUS, has been shown to be identical to hnRNP P2 (Calvio et al., 1995) , which is present in complexes leading to the formation of spliceosomes.
The EWS fusion genes found in human tumors give rise to fusion proteins which all share a common structural pattern: the amino-terminal domain (NTD) of EWS, lacking the RNA-binding domain, is linked to the DNA-binding domain of the transcription factor. Thus the RNA-binding domain of EWS is replaced by a DNA-binding domain. The systematic presence of the DNA-binding domain strongly suggests that these fusion proteins exert their oncogenic potential, at least in part, by deregulating the expression of speci®c target genes. In addition, the EWS ± NTD has been shown to possess an intrinsic transcription activation function when fused to the GAL4 DNA-binding domain (May et al., 1993; Bailly et al., 1994) , further suggesting that the fusion proteins might upregulate the transcription of target genes.
The recurrent t(9;22) chromosomal translocation identi®ed in extraskeletal myxoid chondrosarcoma was found to generate a fusion gene between EWS and the orphan nuclear receptor TEC (for Translocated in Extraskeletal Chondrosarcoma, also called CHN and MINOR, Labelle et al., 1995; Hevdat and Irving, 1995; Clark et al., 1996) . TEC is the human homolog of the rat NOR-1 receptor (Ohkura et al., 1994) , and is a member of a subfamily which includes two other receptors, the rat NGFI-B and mouse NURR1 receptors (Milbrandt, 1988; Law et al., 1992) . Although no ligands have yet been identi®ed for these receptors, several observations suggest that they are involved in the control of cell growth and dierentiation. Induction of NGFI-B correlates with dierentiation of rat PC12 cells into neuronal cells upon treatment with nerve growth factor (Milbrandt, 1988) . NURR1 expression is rapidly induced in the regenerating rat liver following partial hepatectomy (Scearce et al., 1993) , as is the expression of TEC in phorbol 12-myristate 13-acetate (PMA) activated human T cells (Zipfel et al., 1989 , in this last reference TEC is referred to as clone pAT229). The DNAbinding domain of these three receptors are almost identical, those of TEC and NURR1 sharing 98% identity, while those of TEC and NGFI-B share 91% identity. This very high degree of identity raises the possibility that these receptors regulate an overlapping set of target genes and that they may dier in their ability to respond to various external stimulatory signals.
One DNA-response element that is recognized by NGFI-B, NURR1 and TEC is the NGFI-B Response Element (NBRE), which was originally identi®ed by a genetic selection scheme in yeast (Wilson et al., 1991; Scearce et al., 1993; Hedvat and Irving, 1995) . The NBRE consists of a single half-site that is bound by the receptors in the form of monomers (Wilson et al., 1993a) . We have compared the DNA-binding and transcriptional activation properties of various isoforms of TEC and the corresponding EWS/TEC fusion proteins to the NBRE. We ®nd that although the addition of the EWS ± NTD to TEC does not signi®cantly alter its DNA-binding properties, it greatly increases its transcriptional activation potential. Co-transfection experiments of mammalian cells with expression and reporter vectors show that EWS/ TEC is approximately 270-fold more active than TEC in stimulating transcription from a NBRE-containing promoter. EWS/TEC may therefore play a role in tumorigenesis by activating the transcription of target genes. Figure 1 shows the various TEC and EWS/TEC isoforms used in this study. The full-length form of TEC contains 626 amino acids (aa), and sequence homology analyses with other nuclear receptors indicate that the activation domain comprises the ®rst 288 aa, the DNA-binding domain the next 93 aa and the ligand-binding domain the last 245 aa. Two isoforms generated by alternative splicing of the TEC primary transcript have been characterized by cDNA and genomic sequence analysis (Labelle et al., 1995; Hedvat and Irving, 1995; Clark et al., 1996; Ohkura et al., 1996) . One isoform designated TECDN lacks the ®rst 30 aa present in the full-length receptor and another designated TECDC lacks the entire carboxyl-terminal domain. This last isoform contains a short carboxylterminal sequence of 25 aa that is absent in the fulllength receptor. A third isoform lacks both extremities and is designated TECDNDC. Two isoforms of EWS/ TEC fusion proteins were studied, one containing the full-length receptor, EWS/TEC, and the other containing the carboxyl-truncated isoform, EWS/TECDC. In both cases, the ®rst 265 aa of EWS are fused to the coding sequence of TEC via an additional 59 aa sequence encoded by a normally 5' untranslated portion of the TEC mRNA present in the fusion transcript (Labelle et al., 1995; Clark et al., 1996) . RT ± PCR analyses have shown that transcripts corresponding to both EWS/TEC and EWS/TECDC isoforms are present in tumor material, although the latter in notably lesser amount than the former (Brody et al., 1997) . This ®nding raises the possibility that both isoforms may be involved in the tumorigenic process.
Results

TEC and EWS/TEC isoforms
DNA-binding of TEC and EWS/TEC isoforms on the NBRE
As expected considering the high degree of identity between their DNA-binding domains, it was previously shown that TEC can bind the DNA-response element recognized by NGFI-B and NURR1, the NBRE, in a band-shift assay (Hedvat and Irving, 1995) . We were interested in determining whether the various isoforms of TEC and EWS/TEC were also capable of binding this element. Figure 2a shows the in vitro translated proteins labeled with 35 S-methionine and Figure 2b the results of band-shift assays using the same in vitro translated but unlabeled proteins. The full-length receptor TEC does indeed bind the NBRE, and this binding is speci®c as it can be competed by an excess of cold B1a oligonucleotide containing the NBRE but not by an excess of cold mB1a oligonucleotide containing a mutant NBRE sequence that is not recognized by TEC (Hedvat and Irving, 1995) . The TECDN isoform also binds the NBRE, however the TECDC isoform binds the NBRE much less eciently, and the TECDNDC isoform almost not at all. These results clearly indicate that either the carboxyl-terminal domain of TEC is required for ecient binding to the NBRE, or that the 25 additional aa present in the TECDC and TECDNDC isoforms exert a negative eect on this binding. Addition of the EWS ± NTD to TEC and TECDC isoforms does not change signi®cantly their DNAbinding characteristics, EWS/TEC binding the NBRE eciently and EWS/TECDC showing much less ecient binding (Figure 2b ). Thus the fusion proteins behave similarly as the native isoforms of TEC with respect to in vitro binding to the NBRE.
Transcriptional activation of TEC and EWS/TEC isoforms
Co-transfections of COS-1 cells and human chondrocytes with expression and reporter vectors were carried Figure 1 Schematic representations of the various TEC and EWS/TEC isoforms used in this study. The full-length receptor TEC is shown at the top with the activation domain (AD), the DNA-binding domain (DBD) and the ligand-binding domain (LBD). The ®rst and last amino acid of each isoform is indicated. TECDN lacks the ®rst 30 aa present in TEC, while TECDC TECDNDC and EWS/TECDC all contain a 25 aa sequence at their carboxyl-terminal end (horizontally hatched boxes) that is not present in the full-length receptor. The two fusion proteins EWS/TEC and EWS/TECDC both possess the EWS ± NTD fused to TEC via a sequence of 59 aa (vertically hatched boxes) encoded by a normally untranslated 5' portion of the TEC mRNA present in the fusion transcript out to compare the ability of the various isoforms to activate transcription from a NBRE-containing promoter. Figure 3 shows that the full-length receptor moderately activates transcription from such a promoter in COS-1 cells, approximately 12-fold over the background level observed with the empty expression vector. The truncated isoforms TECDN, TECDC and TECDNDC are respectively less and less ecient in activating transcription, TECDNDC barely activating 1.5-fold the reporter gene. The EWS/TECDC fusion protein is slightly but signi®cantly more ecient than TECDC in activating transcription (6.9-fold versus 2.1-fold). The EWS/TEC fusion protein however is a highly potent transcriptional activator, activating more than 3000-fold the reporter gene over the background level in COS-1 cells. When compared to TEC, EWS/TEC is approximately 270-fold more active on the NBRE-containing promoter.
The co-transfection experiments were also carried out in an immortalized human chondrocyte cell line, C-20/A4 (Figure 3 , Goldring et al., 1994) . Such a cell line was used because the cellular origin of chondrosarcomas are chondrocytes, thus we were interested in analysing the activity of the fusion proteins in a cellular context resembling as much as possible the one in which they occur in vivo. Although lower transcriptional activation levels are observed in these cells, the results are similar to that obtained with COS-1 cells: addition of the EWS ± NTD to TECDC slightly but signi®cantly increases its activation potential (threefold versus 0.8-fold), whereas addition of the same EWS ± NTD to TEC converts the receptor into a strong transcriptional activator (134-fold versus 2.5-fold).
To con®rm that the elevated transcriptional activation levels observed with the EWS/TEC fusion protein are due to the presence of the EWS ± NTD and not to the 59 additional aa sequence encoded by the normally 5' untranslated portion of the TEC mRNA present in the fusion transcript, deletion mutant cDNAs were constructed lacking progressively larger portions of the EWS ± NTD (Figure 4c ). These deletion mutants cDNAs were produced by PCR and the ampli®ed portions were sequenced to ensure that no mutations had been introduced in the ampli®cation process. The truncated proteins were translated in vitro (Figure 4a ) and tested in a band-shift assay (Figure 4b ) to con®rm that each of them could bind the NBRE with comparable anity. The expression vectors encoding these constructs were used in co-transfection assays of COS-1 cells and the results show that deleting only the ®rst 65 aa of the EWS ± NTD out of the 265 aa present results in a loss of more than 75% of the transcriptional activation potential of the full-length fusion protein (Figure 4c ). Progressively larger deletions result in even lower activation eciencies, and -Luc reporter vector and the pCMV-Gal normalizing vector. Luciferase activity was normalized with galactosidase activity to correct for transfection eciencies. Each transfection was performed six independent times and the mean value was plotted along with the standard deviation (vertical bars). Fold induction is relative to the empty expression vector. The results show that EWS/TEC transactivates the reporter gene more than 3000-fold in COS-1 cells when only the 59 additional aa sequence is present at the amino-terminal end of TEC, the transcriptional activation level is even lower than that of TEC alone. These results con®rm that the addition of the EWS ± NTD to TEC converts this receptor into a highly potent transcriptional activator.
A deletion analysis was also carried out to determine if the low binding capacity of the TECDC isoform on the NBRE (Figure 2b ) was due to the presence of the 25 additional aa found at the carboxyl-terminal end of the short isoform or to the absence of the carboxylterminal domain of the full-length protein. Figure 5a shows a schematic diagram of TEC, TECDC and a TECDC deletion mutant lacking the last 29 aa, and therefore called TECDC(729). Figure 5b shows the corresponding in vitro translated products and Figure  5c band-shift assays of these proteins on the NBRE. The results clearly show that removing the last 29 aa of TECDC restores the ability of the protein to bind the NBRE. Thus this short aa sequence exerts a negative eect on the DNA-binding capacity of TECDC. To determine if removal of this sequence had any eect on the transcriptional activation potential of TECDC, cotransfection experiments were carried out in COS-1 and C20 cells. The results show that in both cell lines, there is no signi®cant dierence between the transcriptional activation properties of TECDC and TECDC(729) (Figure 5d ). Therefore although TECDC(729) binds the NBRE as eciently as TEC, it is unable to activate transcription to a similar level, suggesting that sequences in the carboxyl-terminal domain of TEC are involved in the transcriptional activation potential of the full-length receptor. S-methionine were separated on a 8% polyacrylamide-SDS gel, and the gel was dried and exposed to an X-ray ®lm. (b) 2 ml of the indicated unlabeled in vitro translated proteins were used in band-shift assays with 0.6 ng of 32 P-labeled B1a oligonucleotide. The EWS ± NTD deletion mutants retain the capacity to bind the NBRE. (c) Vectors encoding the dierent truncated proteins were used in transfection experiments in COS-1 cells as described in Figure 3 . The mean of six independent transfection experiments was used for each construction and the activity of the full-length EWS/TEC fusion protein was normalized to 100%. The results show that deleting the ®rst 65 aa of the EWS ± NTD results in a loss of more than 75% of the transcription activation potential of the full-length fusion protein S-methionine were separated on a 8% polyacrylamide-SDS gel, and the gel was dried and exposed to an X-ray ®lm. (c) 2 ml of the indicated unlabeled in vitro translated proteins were used in band-shift assays with 0.6 ng of 32 P-labeled B1a oligonucleotide. The TECDC(729) deletion mutant eciently binds the NBRE. (d) Vectors encoding the indicated proteins were used in transfection experiments in COS-1 (left panel) and C20 (right panel) cells as described in Figure 3 . Each transfection was performed ®ve independent times and the mean value was plotted along with the standard deviation (vertical bars). The results show that there is no signi®cant dierences between the transactivation potential of TECDC and TECDC(729)
Discussion
In this report we have analysed the DNA-binding and transcription activation potential of various TEC and EWS/TEC isoforms on the NGFI-B Response Element, the NBRE. We show that one isoform of TEC, TECDC, binds much less eciently the NBRE than does the full-length receptor, and that this lack of binding is due to the repressive eect of a short 25 aa sequence present at the carboxyl-terminal end of TECDC. This observation raises the possibility that in vivo the role of this isoform may be to compete with the full-length receptor for cellular factors binding the amino-terminal domain. Interestingly, a short isoform of NURR1 lacking the carboxyl-terminal extremity has also been described (Castillo et al., 1997) , suggesting that such carboxyl-truncated isoforms may be a general feature of this subclass of nuclear receptors.
Addition of the EWS ± NTD to native TEC isoforms does not signi®cantly alter their capacity to bind the NBRE in vitro. It does however have an eect on the transcriptional activation potential of the isoforms. A modest but signi®cant increase in transactivation potential is observed when the EWS ± NTD is fused to TECDC, and a dramatic increase, approximately 270-fold, is seen when it is fused to the full-length receptor. This 270-fold transcription activation potential displayed by EWS/ TEC versus TEC is observed in COS-1 cells, whereas using the human chondrocyte cell line C-20/A4, EWS/ TEC is approximately 50-fold more active than TEC. This variation may re¯ect either a dierence in the transcription and/or translation eciency of the fusion protein between the two cell lines, or by the presence and/or availability of various basal transcription factors interacting with the EWS ± NTD. Interestingly in this respect, it was recently shown that EWS may associate with the basal transcription factor TFIID, which is composed of the TATA-binding protein and its associated factors, as well as with the RNA polymerase II complex (Bertolotti et al., 1998) .
Deletion analyses of the EWS ± NTD in the EWS/ TEC fusion protein show that in our conditions, deleting only the ®rst 65 aa out of 265 aa reduces the transcription activation potential of the resulting protein by more than 75%. This is consistent with results obtained by others with EWS/ATF-1: deleting the ®rst 109 aa of the EWS ± NTD of this fusion protein out of 325 aa reduces the transcription activation levels to almost background (Fukimura et al., 1996) . However, the situation appears dierent for the EWS/FLI-1 fusion protein: in one study, deleting various portions of the EWS ± NTD in EWS/FLI-1 did not signi®cantly alter the transcription activation potential of the resulting protein (Ohno et al., 1993) . In another study concerning EWS/FLI-1, the region in the EWS ± NTD associated with transcription activation was localized to amino acids 82 ± 265 (Lessnick et al., 1995) . Taken together, these results suggest that dierent regions of the EWS ± NTD may play dierent roles depending in which fusion protein they occur.
RT ± PCR analyses have shown that TEC was not expressed in an extraskeletal myxoid chondrosarcoma tumor containing the t(9;22) chromosomal translocation (Brody et al., 1997) . We have shown in this report that addition of the EWS ± NTD to TEC does not alter its DNA-binding properties on the NBRE. Taken together, these results suggest that the EWS/TEC fusion proteins may induce tumorigenesis in chondrosarcomas by activating the expression of TEC target genes not normally expressed in the target issue. Considering the very high homology between the DNA-binding domains of TEC, NGFI-B and NURR1, it is conceivable that these receptors share an overlapping set of target genes. No putative target genes have yet been identi®ed for TEC or NURR1, however three have been identi®ed for NGFI-B. This receptor appears to regulate the expression of the gene encoding the steroid enzyme 21-hydroxylase in adrenocortical cells (Wilson et al., 1993b) , which is involved in the synthesis of the steroid hormones glucocorticoids and mineralocorticoids. Another gene whose transcription may be regulated by NGFI-B encodes the proline-rich protein R15, which is expressed exclusively in the salivary acinar cells in rodents (Lin et al., 1996) . Finally, NGFI-B has been reported recently to be implicated in the transcriptional regulation of the human bi-phosphate aldolase C gene in neuroblastoma cells (Buono et al., 1997) . None of those putative target genes appear a likely candidate for an implication in chondrosarcomas: two encode metabolic enzymes, whereas the third encodes a structural protein. We are currently establishing cellular models for the expression of TEC and EWS/ TEC isoforms in various cell types in order to identify the target genes involved in the development of chondrosarcoma tumors possessing the t(9;22) chromosomal translocation.
Materials and methods
Cell lines
COS-1 cells were maintained in DMEM with 10% FBS and the human chondrocyte cell line C-20/A4 (Goldring et al., 1994) in DMEM/F12 (1 : 1) with 10% FBS. Both culture medium were supplemented with 100 units/ml penicillin G, 100 mg/ml streptomycin sulfate and 0.25 mg/ml amphotericin B.
Coupled in vitro transcription/translation and band-shift assay cDNAs encoding various isoforms of TEC and EWS/TEC were constructed and cloned into the expression vector pcDNA3.1(+) (Invitrogen) and the resulting plasmids were used to program a TNT T7 RNA Polymerase Coupled Reticulocyte Lysate System (Promega) according to the manufacturer's recommendations. Proteins were translated in presence of labeled 35 S-methionine for SDS ± PAGE analysis and in absence of labeled precursor for band-shift assays. Band-shift assays were performed in 20 ml of 10 mM Tris pH 8.0/40 mM KCl/0.05% NP-40/1 mM DTT/10 ng/ml poly dI : dC/6% glycerol. The oligonucleotide B1a containing the NBRE (underlined: 5'-gagttttaaaaggtcatgctaatttgg-3') was 32 P-end labeled with the T4 polynucleotide kinase (New England Biolabs, Beverly, MA, USA) and added to each binding reaction. An oligonucleotide containing a mutant NBRE site was used for competition experiments (mB1a: 5'-gagttttaagaggtcatgctca-atttgg-3'). Binding reactions were carried out for 30 min on ice and loaded onto 4% nondenaturing polyacrylamide gels. Migration conditions were 150 V for 2 h in 0.56TBE buer, and the gels were subsequently ®xed, dried and exposed to X-ray ®lms.
Transfections COS-1 and C-20/A4 cells were transfected in 6-wells cell culture plates by the calcium phosphate precipitation procedure (Graham and van der Eb, 1973) . Approximately 25 ng of expression vectors used for in vitro translation were co-transfected with 400 ng of a reporter vector containing eight copies of the NBRE placed upstream of an inactive basal prolactin promoter-luciferase gene construct (p(B1a) 8 -Luc, Wilson et al., 1991) , and 200 ng of a normalizing vector containing a CMV promoter-b-galactosidase gene construct (pCMV-Gal). Cells were transfected overnight and 48 h later extracts were prepared and enzymatic activities measured using a Luciferase Assay System (Promega), a Luminescent b-galactosidase Detection Kit (Clontech) and a Berthold MiniLumat at LB 9506 Luminometer. Luciferase relative light units were normalized for b-galactosidase activities to correct for transfection eciencies.
